S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:CRTX

Cortexyme Competitors

$36.37
+1.18 (+3.35 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$32.59
Now: $36.37
$37.06
50-Day Range
$29.37
MA: $37.10
$49.21
52-Week Range
$26.66
Now: $36.37
$58.99
Volume464,177 shs
Average Volume309,959 shs
Market Capitalization$1.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.95

Competitors

Cortexyme (NASDAQ:CRTX) Vs. BEAM, RLAY, SWTX, RVMD, NK, and EDIT

Should you be buying CRTX stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Cortexyme, including Beam Therapeutics (BEAM), Relay Therapeutics (RLAY), SpringWorks Therapeutics (SWTX), Revolution Medicines (RVMD), NantKwest (NK), and Editas Medicine (EDIT).

Beam Therapeutics (NASDAQ:BEAM) and Cortexyme (NASDAQ:CRTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Profitability

This table compares Beam Therapeutics and Cortexyme's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Beam Therapeutics-529,075.00%-103.41%-48.05%
CortexymeN/A-37.78%-35.24%

Earnings and Valuation

This table compares Beam Therapeutics and Cortexyme's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$20,000.00212,996.07$-78,330,000.00($14.05)-5.23
CortexymeN/AN/A$-36,980,000.00($1.94)-18.75

Cortexyme has lower revenue, but higher earnings than Beam Therapeutics. Cortexyme is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Beam Therapeutics and Cortexyme, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Beam Therapeutics03302.50
Cortexyme21402.29

Beam Therapeutics currently has a consensus target price of $96.00, suggesting a potential upside of 30.63%. Cortexyme has a consensus target price of $50.00, suggesting a potential upside of 37.48%. Given Cortexyme's higher possible upside, analysts clearly believe Cortexyme is more favorable than Beam Therapeutics.

Insider & Institutional Ownership

49.8% of Beam Therapeutics shares are held by institutional investors. Comparatively, 55.5% of Cortexyme shares are held by institutional investors. 0.7% of Beam Therapeutics shares are held by company insiders. Comparatively, 19.8% of Cortexyme shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Cortexyme beats Beam Therapeutics on 9 of the 12 factors compared between the two stocks.

Relay Therapeutics (NASDAQ:RLAY) and Cortexyme (NASDAQ:CRTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Earnings & Valuation

This table compares Relay Therapeutics and Cortexyme's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relay TherapeuticsN/AN/AN/AN/AN/A
CortexymeN/AN/A$-36,980,000.00($1.94)-18.75

Analyst Recommendations

This is a summary of current recommendations and price targets for Relay Therapeutics and Cortexyme, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Relay Therapeutics01502.83
Cortexyme21402.29

Relay Therapeutics presently has a consensus target price of $57.40, suggesting a potential upside of 43.54%. Cortexyme has a consensus target price of $50.00, suggesting a potential upside of 37.48%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Relay Therapeutics is more favorable than Cortexyme.

Profitability

This table compares Relay Therapeutics and Cortexyme's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Relay TherapeuticsN/AN/AN/A
CortexymeN/A-37.78%-35.24%

Insider and Institutional Ownership

98.4% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 55.5% of Cortexyme shares are owned by institutional investors. 19.8% of Cortexyme shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Relay Therapeutics beats Cortexyme on 6 of the 7 factors compared between the two stocks.

Cortexyme (NASDAQ:CRTX) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cortexyme and SpringWorks Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cortexyme21402.29
SpringWorks Therapeutics00303.00

Cortexyme presently has a consensus price target of $50.00, suggesting a potential upside of 37.48%. SpringWorks Therapeutics has a consensus price target of $91.00, suggesting a potential upside of 31.31%. Given Cortexyme's higher possible upside, research analysts plainly believe Cortexyme is more favorable than SpringWorks Therapeutics.

Insider and Institutional Ownership

55.5% of Cortexyme shares are owned by institutional investors. Comparatively, 76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 19.8% of Cortexyme shares are owned by insiders. Comparatively, 51.2% of SpringWorks Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Cortexyme has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

Valuation and Earnings

This table compares Cortexyme and SpringWorks Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CortexymeN/AN/A$-36,980,000.00($1.94)-18.75
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-19.52

SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Cortexyme, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cortexyme and SpringWorks Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CortexymeN/A-37.78%-35.24%
SpringWorks TherapeuticsN/A-24.48%-23.58%

Summary

Cortexyme beats SpringWorks Therapeutics on 6 of the 11 factors compared between the two stocks.

Revolution Medicines (NASDAQ:RVMD) and Cortexyme (NASDAQ:CRTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Profitability

This table compares Revolution Medicines and Cortexyme's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revolution Medicines-191.17%-32.25%-20.55%
CortexymeN/A-37.78%-35.24%

Institutional and Insider Ownership

85.8% of Revolution Medicines shares are owned by institutional investors. Comparatively, 55.5% of Cortexyme shares are owned by institutional investors. 19.8% of Cortexyme shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Revolution Medicines and Cortexyme, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revolution Medicines01402.80
Cortexyme21402.29

Revolution Medicines presently has a consensus price target of $50.75, suggesting a potential upside of 19.55%. Cortexyme has a consensus price target of $50.00, suggesting a potential upside of 37.48%. Given Cortexyme's higher possible upside, analysts clearly believe Cortexyme is more favorable than Revolution Medicines.

Earnings & Valuation

This table compares Revolution Medicines and Cortexyme's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$50.04 million56.31$-47,660,000.00N/AN/A
CortexymeN/AN/A$-36,980,000.00($1.94)-18.75

Cortexyme has lower revenue, but higher earnings than Revolution Medicines.

Summary

Revolution Medicines beats Cortexyme on 5 of the 9 factors compared between the two stocks.

Cortexyme (NASDAQ:CRTX) and NantKwest (NASDAQ:NK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Valuation & Earnings

This table compares Cortexyme and NantKwest's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CortexymeN/AN/A$-36,980,000.00($1.94)-18.75
NantKwest$40,000.0070,166.82$-65,790,000.00($0.70)-36.79

Cortexyme has higher earnings, but lower revenue than NantKwest. NantKwest is trading at a lower price-to-earnings ratio than Cortexyme, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cortexyme and NantKwest, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cortexyme21402.29
NantKwest00103.00

Cortexyme presently has a consensus price target of $50.00, suggesting a potential upside of 37.48%. NantKwest has a consensus price target of $18.00, suggesting a potential downside of 30.10%. Given Cortexyme's higher probable upside, equities research analysts clearly believe Cortexyme is more favorable than NantKwest.

Insider & Institutional Ownership

55.5% of Cortexyme shares are owned by institutional investors. Comparatively, 9.4% of NantKwest shares are owned by institutional investors. 19.8% of Cortexyme shares are owned by insiders. Comparatively, 71.7% of NantKwest shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Cortexyme has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, suggesting that its stock price is 161% more volatile than the S&P 500.

Profitability

This table compares Cortexyme and NantKwest's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CortexymeN/A-37.78%-35.24%
NantKwest-76,658.58%-56.06%-46.93%

Summary

Cortexyme beats NantKwest on 8 of the 13 factors compared between the two stocks.

Editas Medicine (NASDAQ:EDIT) and Cortexyme (NASDAQ:CRTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Institutional and Insider Ownership

87.5% of Editas Medicine shares are held by institutional investors. Comparatively, 55.5% of Cortexyme shares are held by institutional investors. 0.9% of Editas Medicine shares are held by company insiders. Comparatively, 19.8% of Cortexyme shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Editas Medicine and Cortexyme's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Editas Medicine$20.53 million132.43$-133,750,000.00($2.68)-15.06
CortexymeN/AN/A$-36,980,000.00($1.94)-18.75

Cortexyme has lower revenue, but higher earnings than Editas Medicine. Cortexyme is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Editas Medicine and Cortexyme's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Editas Medicine-99.62%-26.74%-16.38%
CortexymeN/A-37.78%-35.24%

Volatility & Risk

Editas Medicine has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500. Comparatively, Cortexyme has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Editas Medicine and Cortexyme, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Editas Medicine34302.00
Cortexyme21402.29

Editas Medicine presently has a consensus target price of $49.2222, suggesting a potential upside of 21.96%. Cortexyme has a consensus target price of $50.00, suggesting a potential upside of 37.48%. Given Cortexyme's stronger consensus rating and higher possible upside, analysts clearly believe Cortexyme is more favorable than Editas Medicine.

Summary

Cortexyme beats Editas Medicine on 8 of the 13 factors compared between the two stocks.


Cortexyme Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$73.49+14.0%$4.26 billion$20,000.00-5.23High Trading Volume
RLAY
Relay Therapeutics
1.8$39.99+3.5%$3.60 billionN/A0.00
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$69.30+7.8%$3.39 billionN/A-39.83Analyst Report
Revolution Medicines logo
RVMD
Revolution Medicines
1.6$42.45+1.7%$2.82 billion$50.04 million0.00Earnings Announcement
Analyst Report
NantKwest logo
NK
NantKwest
1.1$25.75+3.2%$2.81 billion$40,000.00-36.27Decrease in Short Interest
Gap Up
Editas Medicine logo
EDIT
Editas Medicine
1.4$40.36+6.9%$2.72 billion$20.53 million-23.20Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$61.01+12.9%$2.69 billion$125.57 million-35.68Earnings Announcement
Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.81+3.0%$2.47 billion$31.43 million-6.03Gap Up
AlloVir logo
ALVR
AlloVir
1.4$34.53+7.5%$2.25 billionN/A0.00Insider Selling
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86+1.9%$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92+8.7%$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94+5.0%$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41+4.2%$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60+1.7%$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.97+16.6%$1.69 billionN/A-6.06Analyst Report
Unusual Options Activity
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07+2.5%$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23+0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65+16.2%$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29+0.8%$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30+1.3%$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21+2.4%$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42+8.4%$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89+0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25+1.0%$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08+7.0%$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62+9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25+1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18+0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96+3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56+9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25+1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43+2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40+7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73+8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40+10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54+12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31+4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06+6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29+4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01+4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92+7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86+7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29+6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61+8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16+7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02+3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28+17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16+9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02+7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13+6.4%$537.00 million$10 million-11.13Increase in Short Interest
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.